Previous 10 | Next 10 |
Company selected RLY-2608 as PI3Kα mutant inhibitor development candidate and plans to initiate first-in-human study in the first half of 2022 RLY-2608 potently inhibits mutants H1047X, E542X, and E545X, which affect over 100,000 patients annually in the U.S. Rela...
CAMBRIDGE, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading edge computational and experimental technologies, plans to report second quarter 2021 fin...
CAMBRIDGE, Mass., June 02, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in fireside chats at the Goldman Sachs 42 nd Annual Global Healthcare Conference on Thursday, June 10, 2021 at 3:50 pm ET and at the JMP Securities Life Science Co...
CAMBRIDGE, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in a fireside chat at the Cowen 2 nd Annual Virtual Oncology Innovation Summit on Thursday May 20, 2021 at 11:20am ET. The fireside chat will be webcast live and ma...
Relay Therapeutics (RLAY): Q1 GAAP EPS of -$0.47 misses by $0.01.Revenue of $0.95MCash, cash equivalents and investments totaled approximately $726.1 MPress Release For further details see: Relay Therapeutics EPS misses by $0.01
CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading edge computational and experimental technologies, today reported first quarter 2021 financ...
CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading edge computational and experimental technologies, today announced the appointment of Patri...
CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in a fireside chat at the Bank of America 2021 Health Care Conference on Tuesday, May 11, 2021 at 8:45 a.m. ET. The fireside chat will be webcast live and may be access...
I operate two main portfolios: my "safe" portfolio and my high growth portfolio. This article will dissect and focus on my high-growth holdings. I generally like to invest in themes and tend to take a shotgun approach to my holdings in emerging sectors. I will list my holdings for 8 s...
CAMBRIDGE, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading edge computational and experimental technologies, today announced the appointments of ...
News, Short Squeeze, Breakout and More Instantly...
Relay Therapeutics Inc. Company Name:
RLAY Stock Symbol:
NASDAQ Market:
2024-05-10 16:30:03 ET Oppenheimer analyst issues MARKET OUTPERFORM recommendation for RLAY on May 10, 2024 02:00PM ET. The previous analyst recommendation was Market Outperform. RLAY was trading at $6.425 at issue of the analyst recommendation. The overall analyst conse...
2024-05-06 09:15:03 ET Oppenheimer analyst issues OUTPERFORM recommendation for RLAY on May 6, 2024 07:53AM ET. The previous analyst recommendation was Outperform. RLAY was trading at $7.04 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today reported first quarter 2024 financia...